Next Article in Journal
A Reminder of an Important Clinical Lesson: Hypoxaemia in a Pleural Effusion
Previous Article in Journal
Acknowledgment to Reviewers of Reports in 2021
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Reports
Volume 5
Issue 1
10.3390/reports5010005
reports-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Sex Hormone-Binding Globulin and Its Association to Cardiovascular Risk Factors in an Italian Adult Population Cohort

by
Brigitta Buttari
1,†,
Rachele Riganò
1,†,
Luigi Palmieri
1,
Cinzia Lo Noce
1,
Stefan Blankenberg
2,3,4,
Tanja Zeller
2,3,5,
Serena Vannucchi
1,
Anna Di Lonardo
1,
Marco Gabbianelli
1 and
Chiara Donfrancesco
1,*
1
Department of Cardiovascular and Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità (Italian National Institute of Health), 00161 Rome, Italy
2
German Center for Cardiovascular Research, Partner Site Hamburg/Lübeck/Kiel, 20251 Hamburg, Germany
3
University Heart and Vascular Center Hamburg, 20246 Hamburg, Germany
4
Population Health Research Center, Medical University Hamburg-Eppendorf, 20246 Hamburg, Germany
5
University Center of Cardiovascular Science, 20246 Hamburg, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Reports 2022, 5(1), 5; https://doi.org/10.3390/reports5010005
Submission received: 13 January 2022 / Revised: 9 February 2022 / Accepted: 10 February 2022 / Published: 14 February 2022
Browse Figure
Versions Notes

Abstract

:
Abnormal sex hormone-binding globulin (SHBG) and sex hormone concentrations are the cause or the consequence of cardiometabolic diseases, however, the clinical correlates of SHBG is clearly less understood. In our study we investigate sex- and age-specific serum SHBG levels and their association with cardiovascular risk (CVR) factors and high-risk conditions in an adult cohort of Italian population. Data from 1176 men and 2236 women, aged 20–81 were analyzed and serum SHBG determined in stored samples using an immunoassay. SHBG concentrations, higher in women than in men in the younger age groups, exhibited a curvilinear increase with age in men and a U-shaped curve across the lifespan in women, with a decrease from the 2nd to the 6th decade of age and an increase after the 6th decade when SHBG concentrations were similar in both sexes. Low SHBG serum levels correlated with the traditional CVR factors diabetes, obesity, and hypertension, whereas high level of SHBG correlated with cholesterol HDL. These associations were more numerous in women than in men, in whom decreased with age. The sex- and age specific differences observed in our population-based cohort should be considered in establishing reference ranges and clinical cut-off points to improve CVR score charts and therapeutic approaches.

1. Introduction

Sex hormone-binding globulin (SHBG) is a glycoprotein that binds sex steroid hormones (testosterone, progesterone and estradiol) and it is produced mainly in the liver. Although the affinity of androgens for SHBG is stronger than that of estrogens [1], SHBG regulates the bioavailability of both hormones modulating the transport of testosterone to target tissues [2]. SHBG synthesis are regulated by hormonal and metabolic factors. Several clinical studies have demonstrated the metabolic function of SHBG. Interest in SHBG has escalated in recent years because of its inverse association with metabolic syndrome and type 2 diabetes in women and men [3,4,5,6]. Moreover, low SHBG serum were linked with cardiovascular disease in men [7]. Although low SHBG serum level in women was associated with poorer cardiovascular health, such endothelial dysfunction, carotid atherosclerosis, and vascular remodeling, greater prevalence of metabolic syndrome, type 2 diabetes, hypertension, the clinical correlates of SHBG in women is less clearly understood [8,9,10].
Further sex-specific research is needed to understand the role of SHBG in the etiology of diabetes type II and in establishing new approaches to target prevention and therapeutic strategies for the improvement of overall cardiovascular health [11,12].
In future research, special attention should be paid in regards to the role of abnormal SHBG and sex hormone levels in women’s cardiovascular health and to elucidate whether the reproductive hormones are the cause or the consequence of cardiometabolic diseases. [10]. Studies with women from the general population are rare and previous studies are mainly conducted in post-menopausal women or in selected community or in patient-based study samples, or in small sample sizes. Furthermore, to our knowledge no studies evaluated SHBG differences across decades of the male and female lifespan in a large Italian population-based cohort.
To overcome these limitations, the distribution of SHBG in the adult Italian population was investigated using data from a cohort of adult general population, Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS), to assess the sex- and age-specific profile of circulating SHBG across the lifespan and to assess the association of SHBG with cardiovascular risk factors and high risk conditions.

2. Materials and Methods

2.1. Study Population

Within the MATISS study, men and women aged 20–81 years were extracted randomly from a geographical area located in Central Italy about 100 km south of Rome and comprised 4 adjacent rural towns (Sezze, Roccagorga, Bassiano, and Priverno) and examined in 1993–1996 collecting socio-demographic characteristics, lifestyles (smoking, diet, physical activity), risk factors (blood pressure, heart rate, ECG read by Minnesota Code, blood lipids, glycemia, body mass index—BMI, pulmonary function), using standardized procedures and methods [13,14,15]. During the screening, serum, plasma, buffy coat, red cells were collected and were stored in liquid nitrogen in the population Biological Bank of the Italian National Institute of Health (ISS). The MATISS study was approved as part of the CUORE Project by Ethical Committee of ISS on 15 March 2006; the Ethical Committee approved the use of pooled samples for research activity in epidemiological and genetic/genomic studies. Personal data were stored and managed according to the European personal data regulation (GDPR 679/2016). Personal data were excluded from the database used for statistical analyses that, instead, includes a unique code for each person. The same codes were used to label the serum samples stored in the biological bank.

2.2. Measurements SHBG and Testosterone

The MATISS cohort was part of MORGAM (MOnica Risk, Genetics, Archiving and Monograph) and BIOMARCARE (Biomarker for Cardiovascular Risk Assessment in Europe) international projects. The BIOMARCARE consortium is an EU-funded consortium including over 30 partners from academia and industry [16]. BiomarCaRE aims to determine the value of established and emerging biomarkers to improve risk estimation of cardiovascular disease in Europe. Within the BIOMARCARE consortium, a large panel of biomarkers was assessed in the MATISS Study to improve disease prediction among different European populations. Among the panel, SHBG and testosterone were assessed in 2016 at the BiomarCaRE Laboratory (University Heart Center Hamburg, Germany) using immunoassays. Briefly, SHBG was measured on the Architect i2000 system using the Abbott Architect SHBG assay and total testosterone on the Abbott ARCHITECT 2nd Generation Testosterone (Abbott Diagnostics, Abbott Park, IL, USA). The tests used chemiluminescent microparticle immunoassay on the ARCHITECT system (Abbott Diagnostics, Abbott Park, IL, USA). The assay ranges were as follows: SHBG, 0–250 nmol/L; Testosterone, 0.45–35 nmol/L. The coefficients of variability (CV): SHBG, intra assay CV 3.79% and inter assay CV 8.2%; Testosterone, intra assay CV 4.3% and inter assay CV 8.38%.

2.3. Statistical Analysis

With the aim to describe age-specific trends of SHBG across the lifespan, the study population was stratified by sex and age classes (20–29, 30–39, 40–49, 50–59, 60–69, 70–81 years-old). Mean, standard deviation, confidence interval of mean, median, minimum, and maximum values were calculated for SHBG in each group. After testing SHBG distribution, Mann–Whitney non-parametric test was used to evaluate statistically significant differences among groups; differences associated to p-values ≤ 0.05 were considered statistically significant.
To study the association between SHBG and cardiovascular diseases risk (CVR) factors and conditions population sample, SHBG was stratified by sex, age classes, and SHBG tertiles. Due to the combination of strata, to avoid excessive fragmentation of the sample size, age groups were aggregated into 20–39, 40–59, and 60–81 years, representing young adults, adults, and the elderly. Within each tertile, cardiovascular risk factors and high-risk conditions were evaluated: body mass index (BMI), diastolic and systolic blood pressure, glycemia, triglyceridemia, cholesterol, testosterone, smoking habits, hypertension, hypercholesterolemia, type 2 diabetes mellitus. In female population, the presence of menopause and use of oral contraceptives were also reported. Mean and standard deviation were assessed for continuous variables, percentages for categorical variables; 95% confidence intervals were used to compare tertiles within age classes and to assess the association between SHBG and risk factors/high risk conditions as well as ANOVA models and chi-squared tests for continuous variables, percentages for categorical variables respectively. Statistical analyses were performed by the use of the software IBM SPSS (version 25) (IBM, New York, NY, USA) and SAS software, release 9.4, (SAS Institute Inc., Cary, North Carolina, NC, USA).

3. Results

3.1. Sex Hormone-Binding Globulin Trends in Males and Females across the Adult Lifespan

Table 1 reports descriptive statistics of circulating SHBG in randomly selected 1176 adult men and 2236 adult women) divided in six age groups. Results demonstrated that SHBG concentrations in men ranged from a value of 8.5 nm/L to a value of 203.2 nm/L and the mean value increased with age from approximately 32 nm/L in the age groups 20–29 and 30–39 years to 57.1 nm/L in the oldest persons (age group 70–81 years) (Table 1 and Figure 1).
The mean value of SHBG in men was 41.2 ± 18.9 nm/L. Considering the results in women we observed that concentrations ranged from a value of 7 nm/L to a value of 249.4 nm/L (Table 1 and Figure 1). In contrast to that observed in males the highest mean value of SHBG (87.6 nm/L) was detected in the younger group of persons (20–29 years). Then the SHBG value decreased gradually with age until 59 years, afterward it started to increase again. The mean value of SHBG in women was 62.6 ± 38.7 nm/L.
Comparison of SHBG distribution by the use of Mann–Whitney non-parametric test showed that SHBG concentrations significantly differed among age groups in both sexes (p < 0.018) with the exception of the first two groups in men and of the groups 40–49 and 70–81 years in women whose values of protein concentration were almost the same.
The comparison between results in men and women showed that SHBG concentrations were higher in women than in men in the lower age groups (p < 0.0001), especially in the age group 20–29 years (Table 1 and Figure 1). From the group 50–59 years values tended to be similar in both sexes (p < 0.002). The differences in SHBG concentrations between men and women were not statistically significant in persons over 60 years of age (Table 1 and Figure 1).

3.2. Sex Hormone-Binding Globulin Levels and Cardiovascular Risk Factors and Conditions

In Table 2, distribution of persons in each group of sex, age (20–39, 40–59, 60–81 years-old), and SHBG tertiles were reported as well as SHBG minimum and maximum. Of note, only in the age group 60–81 years, SHBG values were almost overlapping in men and women (Table 2).
Cardiovascular risk factors and high-risk conditions were reported in Table 3 and Table 4 by age class and SHBG tertile, respectively for men and women. In men, testosterone was highly significant (p < 0.0001) across SHBG tertiles in all of the three age groups, whereas BMI significantly decreased in the third tertile in all of the three age groups with particular relevance to the age group 20–39 years. Of note, the prevalence of smoking habits was high in all groups. Prevalence of smoking habit in men was higher in the third tertile than in the first tertile. In the age group 20–39 years, men within the highest tertile had significantly lower blood pressure (BP) (systolic and diastolic) in comparison to those within the lowest tertile. In addition, prevalence of hypertension tended to be lower when concentration of SHBG increased. In the older age group (60–81 years), glycemia and triglyceride values resulted significantly lower in the third than in the first tertile. Of note, in the same older age group prevalence of diabetes was lower in comparison to other tertiles when concentration of SHBG increased.
In women, in all the age groups, SHBG was associated with several risk factors and high-risk conditions. Analysis across SHBG tertiles determined that all the three age groups shared the presence of an inverse association of SHBG serum concentration (lower level of SHBG) with diastolic BP, BMI, glycemia, diabetes, and a direct association (higher level of SHBG) with cholesterol HDL. According to the World Health Organization (WHO) (2000) standards [17] the analysis of the BMI showed that overweight (BMI < 30) and obese (BMI > 30.0) conditions tended to be lower in women when concentration of SHBG increased across tertiles. The age groups 20–39 and 40–59 years shared the presence of a negative association of SHBG with the prevalence of hypertension. Of note, across tertiles, women taking contraceptive drugs shared the presence of a positive association with SHBG. Unexpectedly, in the age group 20–39 years, cholesterol resulted lower in the SHBG first and second tertile than in the third tertile, the prevalence of hypercholesterolemia was lower in the second tertile than in the first and third tertile and the prevalence of hypertension was lower in the second than in the third tertile. In the age group 30–49 years, we observed that higher SHBG concentrations were associated to lower systolic BP and as well as to higher number of smokers and of women with menstrual cycles. In the age group 60–81 years, we found a positive association of SHBG concentration with low systolic BP.

4. Discussion

Sex hormone-binding globulin is a major carrier of sex hormones in human plasma [18] and its concentration changes with age [18,19]. Evidence indicates that a low serum level of SHBG may be associated with increased risk of cardiovascular disease in both women and men.
To date, epidemiological studies reporting significant associations of SHBG with CVR factors and high-risk conditions were predominantly sex-specific or conducted in small, selected study samples. The present study determined the distribution of serum SHBG across decades of adult male and female lifespan in a large prospective cohort of central Italy population at enrollment in 1993–1996 and investigated the relationship of SHBG with the distribution of cardiovascular risk factors and prevalence of high-risk conditions. The results of this study demonstrate the presence of gender differences as concern blood SHBG concentration (mean value and trend during the lifespan) and its associations with risk factors and conditions, more numerous in women than in men. To our knowledge this is the first study evaluating SHBG differences across decades of the male and female lifespan in a large Italian population-based cohort. The relationship of SHBG with age is well documented and clear in men [18,20,21] whereas data in women are few and controversial and are referred mainly in peri-menopausal women [22,23,24,25,26,27].
The MATISS data in men confirm in a larger Caucasian population previous findings from Harman et al. who determined on a population of 890 men from the Baltimore Longitudinal Study on Aging that SHBG exhibits a curvilinear increase with age, rising at a slightly greater rate in the older than in younger men [18]. Our data in men are also in accordance with recent findings on a population-based sample of 6296 men aged 40 years–79 years old from China, who describe the same positive correlation between SHBG level and age [21]. In contrast, data from an Australian population of more than 110,000 persons with an age range between 10 and 90 years showed that SHBG declines to a nadir in males at the age of 20 years and remains stable till the 6th decade with a gradual progressive rise thereafter [20]. As concerning women, our results here agree with most studies describing a U-shaped curve for SHBG across the lifespan of women, with a decrease from the 2nd to the 6th decade and an increase after the 6th decade [28]. Interestingly, Maggio et al., in their study [28], observed in the group of women between 20 and 60 years that BMI and insulin had opposite trajectories to SHBG, thus suggesting that in part insulin levels and BMI negatively influenced SHBG concentration. A previous study from Davison et al., showed no substantial change in SHBG levels across the lifespan of Australian women, apart from a slight increase in the oldest [24]. In the more recent Australian population study by Handelsman et al., SHBG reached a nadir early, in late adolescence, with median levels rising progressively with age and with an acceleration after the age of 70 years [20]. In the same study, women exhibited a serum SHBG peak during the early half of reproductive life due to pregnancy or to the use of oral contraceptives. It was reported that at the menopausal transition, women experience a drastic decrease in the level of SHBG as well as a concomitant but more gradual decrease in total testosterone thus acquiring a more androgenic profile of sex hormones (higher free testosterone and lower SGBG levels) [29]. This profile is associated with adverse CVR factors levels. Our data showing that testosterone levels do not change in women over the course of life suggests that other key risk factors may be involved in the occurrence of cardiovascular diseases in Italian female population.
Current literature reports that among CVR factors and high risk conditions, components of metabolic syndrome are associated to SHBG levels in both sexes with a threefold increase in cardiovascular disease risk and a fivefold increase to develop type 2 diabetes [30]. Low SHBG levels are reported as an independent risk factor for insulin resistance and diabetes. The correlation between SHBG and insulin resistance was demonstrated in many cross-sectional studies, suggesting that the association between SHBG and type 2 diabetes was due to insulin resistance [4,31]. Moreover, this inverse association is stronger in women than in men [11]. In a later study, Ding et al., demonstrated that in post-menopausal women, higher levels of SHBG were strongly associated with decreased risk of type 2 diabetes, as observed in men (4). In our female sample population, we found that glycemia was inversely associated to SHBG in all the three age groups and that low concentration of SHBG were associated with a higher prevalence of diabetes. Genetic studies have also strengthened the evidence that SHBG and sex hormones are involved in the etiology of type 2 diabetes [4,32].
Low SHBG levels have also been associated to an adverse lipid profile. Many studies have shown that SHBG levels correlate positively with HDL-cholesterol concentration. A cross-sectional study on 79 morbidly obese Italian persons, 27 men and 52 women (age 30–45 years) demonstrated that an increase in SHBG levels might be related to an increment of HDL-cholesterol [33]. According with this study, the increment of HDL was observed among SHBG tertiles in women whereas it was not observed in men. A possible explanation may be ascribed to the different BMI showed by men and women (normal-weight vs. over-weight) from MATISS population.
An unexpected and apparently contrasting result, which deserves further investigation, is that in the younger group of women (20–39 years) cholesterol concentration and the prevalence of hypercholesterolemia are higher in the highest SHBG tertile than in the first tertile. A possible explanation may be ascribed to hormonal contraceptive use that is reported positively associated with lipoprotein subclasses, including HDL and total cholesterol, although the metabolic perturbations are reversed upon discontinuation [34].
It is well documented that in women CVR presents a rapid increase with the onset of menopause. In the perimenopausal period, a large number of women suffer from metabolic syndrome, that conveys a fourfold higher risk of cardiovascular events in women than in men [35]. A very recent cross-sectional study [36] investigating associations of sex hormones and anthropometric markers in the general population in Pomerania, demonstrated the presence of inverse associations of serum SHBG with multiple body parameters, such as subcutaneous adipose tissue, BMI and waist-circumference, in both women and men, thus supporting a role for low SHBG in incremented obesity risk in men and widening this result also to women [10]. In another very recently published paper, in 270 men (29% blacks) and 304 women (34% blacks) from the Heritage Family study, low SHBG and testosterone were associated with higher adiposity and abdominal and visceral fat in men and a similar adiposity profile was observed in women with low SHBG [37]. In our study, we confirmed the presence of the previously reported inverse association between SHBG and BMI in women, association that we found independent of age because it was present in all the three age groups. In men, many previous studies with cross-sectional and longitudinal design report that SHBG, as well as testosterone, was inversely associated with metabolic syndrome and many of its components, although the inverse associations with the sex hormones were not always found across the different component of metabolic syndrome. Associations with metabolic syndrome were primarily mediated by hyperglycemia, hypertriglyceridemia, abdominal obesity and were weaker for hypertension [30,38,39,40]. In a meta-analysis of 20 observational studies, Brand et al. observed that SHBG concentrations decreased with increasing BMI [38]. Ding et al. demonstrated in two prospective studies that higher levels of SHBG in men were strongly associated with decreased risk of type 2 diabetes [4,11]. An epidemiological study conducted on a representative sample of the population living in the Tuscany region of Italy (InCHIANTI study) to investigate the association between hormones and metabolic syndrome in older Italian men (mean age: 75 years; age range: 65–96) demonstrated that total testosterone and SHBG were negatively associated with metabolic syndrome [41] and independent of age, SHBG was positively associated with HDL and negatively associated with abdominal obesity and triglycerides. In contrast to the InCHIANTI study, a cross-sectional study by Xiao et al. determined that in elderly men, lower SHBG levels but not testosterone may be an independent predictor for the prevalence of metabolic syndrome [36]. In a recent international collaborative study reporting statistical analyses of individual participant data from 12,330 male controls aged 25–85 years from 25 published studies on prostate cancer risk SHBG results inversely associated with BMI and directly associated with age, testosterone, and current smoking [42]. The MATISS Study findings here reported agree with previous studies reporting the presence of an inverse association between SHBG and testosterone and BMI, association that we found in all age groups both men and women. Our results in the group of old-aged men were in line with findings by Brand et al. on the presence of an inverse association between SHBG and glycemia [38], whereas results in the all groups of men confirm the direct association of SHBG with current smoking and with age reported by Watts et al. [42]. Indeed, we observed that in all age groups, men within the third tertile were older than those in the first tertile. Finally, our observations that men in the age group 20–39 years within the highest SHBG tertile have significantly lower BP (systolic and diastolic) in comparison to those within the lowest tertile and that in the all age groups the prevalence of hypertension tend to be lower when concentration of SHBG increases, were in line with results from Siddiqui et al., who found that low SHBG levels were predictive of high risk for developing not only metabolic syndrome but also hypertension [39].
Hypertension is a major CVR factor possibly explaining the increase of cardiovascular disease occurrence in postmenopausal women. In line with this hypothesis, in our study of general population, we found that, blood pressure was inversely associated to SHBG in women, particularly in the group of middle- and old-aged women where we found that both diastolic and systolic blood pressure as well as the prevalence of hypertension significantly decreased across SHBG tertiles. In the younger group of women blood pressure and the prevalence of hypertension seem to be inversely associated to SHBG only in the second SHBG tertile.
Similarly, to what observed in men, the middle age group of women presents a direct association of SHBG with current smoking. This point should be studied further to understand the nature of this association.
In female population we confirm previous findings on the positive association of SHBG with the use of contraceptive drugs or the presence of menstrual cycles in the middle age population [43]. Of note, in our study, the group of the middle-aged women with menstrual cycles was more numerous (51%) in third SHBG tertile, association that we found dependent on age thus confirming previous observation that in premenopausal women estradiol levels take a part in the fine tuning of SHBG level besides age [44].
Even though, several studies have demonstrated the role of endogenous estrogens on the cardiovascular protection [45], information is lacking about the role played by SHBG in the regulation of estradiol. It is important to note that circulating SHBG has functions in addition to the binding and transport of sex steroids. Indeed, recent evidence suggest that SHBG exerts a direct action through its internalization, as well as by influencing estradiol uptake and signaling [46,47]. By interacting with its putative receptors such as low-density lipoprotein-related protein 2 receptor (Megalin receptor) and matrix-associated proteins [48,49], SHBG activates the non-genomic sex hormone intracellular pathways in reproductive tissues/cells. There is also evidence indicating that the SHBG-SHBG receptor-membrane estradiol receptor (ER) complex participates in the estradiol signaling in non-reproductive cells such as lymphocytes and neurons cells [47,50]. On the contrary, SHBG acts as negative modulator of estradiol action in breast cancer thus playing a protective role in the exposure of breast cells to estrogens [51]. Of note, this effect is highly selective, depending on SHBG interaction with cells, and restricted to genes associated to cell growth and estrogen-sensitivity. Another aspect to be considered to explain the biological role played by SHBG is its binding affinity for exogenous chemical compounds that protectively mitigate target tissue exposure thus avoiding the endocrine disrupting potential of these compounds [52]. The displacement of the endogenous ligand by chemicals binding to SHBG could expose target tissues to higher endogenous hormone levels thus potentially resulting in adverse effects. Therefore, studies are needed in non-reproductive cells to establish whether the possible cardiometabolic benefits associated to SHBG are estrogen independent effects or reflect the complex crosstalk between hormonal and metabolic factors.

5. Conclusions

The sex- and age specific differences we found in our population-based cohort should be considered in establishing reference ranges and clinical cut-off points. Further studies regarding SHBG as biomarker for CVD-related risk factor burden are necessary to evaluate individual CVR profile and to consider SHBG as part of CVR score charts. Future research from prospective cohort studies, as well as interventional trials, are also needed to investigate the molecular mechanisms of these associations and to assess their causal direction. For example, an important question that needs to be addressed is whether a low concentration of SHBG causes insulin resistance or whether insulin resistance causes a low SHBG concentration [31]. The elucidation of causality direction could bring to therapeutic perspectives.

Author Contributions

The authors’ responsibilities were as follows—B.B. and R.R. interpreted the results and drafted the manuscript; C.D. prepared the data sent to laboratory, cooperated to the management of serum samples sent to laboratory, coordinate the management of data and statistical analyses, interpreted the results, and revised the manuscript; B.B., R.R. and C.D. performed the statistical analyses, interpreted the results, and revised the manuscript; L.P. cooperated with the management of serum samples sent to laboratory, and revised the manuscript; C.L.N. collected data and biological samples, cooperated with the management of serum samples sent to laboratory, and revised the manuscript; A.D.L. and S.V. handled the biological samples storage and revised the manuscript; S.B. coordinated the funds and the laboratory for analysis of serum samples and revised the manuscript; T.Z. headed the laboratory for the analysis of serum samples and revised the manuscript; M.G. interpreted the results and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

The MATISS Study is part of the CUORE Project—Epidemiology and Prevention of Cardiovascular Disease, funded by the Italian Ministry of Health and coordinated by the Department of Cardiovascular and Endocrine-metabolic Diseases and Aging, Istituto Superiore di Sanita, Rome, Italy. The BiomarCaRE project was funded by the European Union (EU) Seventh Framework Programme (FP7; 2007–2013) under grant agreement no. HEALTH-F2-2011-278913. Parts of the SHBG measurements were funded by the Medical Research Council London (G0601463, no. 80983: Biomarkers in the MORGAM Populations). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Institutional Review Board Statement

The MATISS study was approved as part of the CUORE Project by the Ethic Committee Name: Ethical Committee of the Institute Superiore di Sanità (ISS, the Italian National Institute of Health), 15 March 2006. Approval Code: PRE/96/06, CE-ISS 06-129.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data not available due to restrictions e.g., privacy or ethical.

Acknowledgments

Luigi Palmieri and Chiara Donfrancesco, Department of Cardiovascular and Endocrine-metabolic Diseases and Aging, Istituto Superiore di Sanità (Rome, Italy), are the coordinators of the CUORE Project and those responsible of the ITA-ROM cohorts (including MATISS cohort) within the MORGAM/BiomarCaRE collaboration. The BiomarCaRE laboratory in Hamburg, Germany, is directed by Stefan Blankenberg and headed by Tanja Zeller, whose team carried out the SHBG measurements. The MORGAM/BiomarCaRE Data Centre in Helsinki, Finland, is headed by Kari Kuulasmaa, whose team handled and harmonized the data between the included cohorts and the BiomarCaRE laboratory. Giovanni Veronesi, Department of Medicine and Surgery, University of Insubria (Varese, Italy), is the contact person for some population cohorts, including MATISS, within the MORGAM/BiomarCaRE collaboration. Administrative staff of the Istituto Superiore di Sanità: Claudia Meduri, Tiziana Grisetti, Matilde Bocci, Gabriella Martelli, Valerio Occhiodoro, Maria Grazia Carella, Francesca Meduri. Grateful thanks to Simona Giampaoli, research manager of the Istituto Superiore di Sanita, who founded the CUORE Project and coordinated with dedication the research activities until her retirement in 2018.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Dunn, J.F.; Nisula, B.C.; Rodbard, D. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. 1981, 53, 58–68. [Google Scholar] [CrossRef] [PubMed]
  2. Liu, S.; Sun, Q. Sex differences, endogenous sex-hormone hormones, sex-hormone binding globulin, and exogenous disruptors in diabetes and related metabolic outcomes. J. Diabetes 2018, 10, 428–441. [Google Scholar] [CrossRef] [PubMed]
  3. Laaksonen, D.E.; Niskanen, L.; Punnonen, K.; Nyyssönen, K.; Tuomainen, T.P.; Valkonen, V.P.; Salonen, R.; Salonen, J.T. Testosterone and Sex Hormone-Binding Globulin Predict the Metabolic Syndrome and Diabetes in Middle-Aged Men. Diabetes Care 2004, 27, 1036–1041. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Ding, E.L.; Song, Y.; Manson, J.E.; Hunter, D.J.; Lee, C.C.; Rifai, N.; Buring, J.E.; Gaziano, J.M.; Liu, S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N. Engl. J. Med. 2009, 361, 1152–1163. [Google Scholar] [CrossRef] [Green Version]
  5. Haffner, S.M.; Valdez, R.A.; Morales, P.A.; Hazuda, H.P.; Stern, M.P. Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. J. Clin. Endocrinol. Metab. 1993, 77, 56–60. [Google Scholar]
  6. Lindstedt, G.; Lundberg, P.A.; Lapidus, L.; Lundgren, H.; Bengtsson, C.; Björntorp, P. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM: 12-yr follow-up of population study of women in Gothenburq, Sweden. Diabetes 1991, 40, 123–128. [Google Scholar] [CrossRef]
  7. Kalme, T.; Seppala, M.; Qiao, Q.; Koistinen, R.; Nissinen, A.; Harrela, M.; Loukovaara, M.; Leinonen, P.; Tuomilehto, J. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J. Clin. Endocrinol. Metab. 2005, 90, 1550–1556. [Google Scholar] [CrossRef]
  8. Ouyang, P.; Vaidya, D.; Dobs, A.; Golden, S.H.; Szklo, M.; Heckbert, S.R.; Kopp, P.; Gapstur, S.M. Sex hormone levels and subclinical atherosclerosis in postmenopausal women: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2009, 204, 255–261. [Google Scholar] [CrossRef] [Green Version]
  9. El Khoudary, S.R.; Wildman, R.P.; Matthews, K.; Thurston, R.C.; Bromberger, J.T.; Sutton-Tyrrell, K. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. Atherosclerosis 2012, 225, 180–186. [Google Scholar] [CrossRef] [Green Version]
  10. Kische, H.; Gross, S.; Wallaschofski, H.; Völzke, H.; Dörr, M.; Nauck, M.; Haring, R. Clinical correlates of sex hormones in women: The study of health in Pomerania. Metabolism 2016, 65, 1286–1296. [Google Scholar] [CrossRef]
  11. Ding, E.L.; Song, Y.; Malik, V.S.; Liu, S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2006, 295, 1288–1299. [Google Scholar] [CrossRef] [PubMed]
  12. Ford, E.S.; Liu, S. Invited commentary: Acne in adolescence-Protecting the heart but damaging the prostate later in life? Am. J. Epidemiol. 2005, 161, 1102–1106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Rossi, B.; Lo Noce, C.; Donfrancesco, C.; Palleschi, S.; Giampaoli, S.; Tripepi, G.; Spoto, B.; Palmieri, L.; Pannozzo, F.; Zoccali, C. Estimated Glomerular Filtration Rate, All-Cause Mortality and Cardiovascular Diseases Incidence in a Low Risk Population: The MATISS Study. PLoS ONE 2013, 8, e78475. [Google Scholar]
  14. Giampaoli, S.; Poce, A.; Sciarra, F.; Lo Noce, C.; Dima, F.; Minoprio, A.; Santaquilani, A.; Caiola De Sanctis, P.; Volpe, R.; Menditto, A.; et al. Change in cardiovascular risk factors during a 10-year community intervention program. Acta Cardiol. 1997, 52, 411–422. [Google Scholar]
  15. Giampaoli, S.; Urbinati, G.C.; Menotti, A.; Ricci, G.; Pasquali, M. Short term changes in cardiovascular risk factors in the DI.S.CO. intervention project. Eur. J. Epidemiol. 1991, 7, 372–379. [Google Scholar] [CrossRef]
  16. Zeller, T.; Hughes, M.; Tuovinen, T.; Schillert, A.; Conrads-Frank, A.; den Ruijter, H.; Schnabel, R.B.; Kee, F.; Salomaa, V.; Siebert, U.; et al. BiomarCaRE: Rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries. Eur. J. Epidemiol. 2014, 29, 777–790. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation; World Health Organization: Geneva, Switzerland, 2000. [Google Scholar]
  18. Anderson, D.C. Sex-Hormone-Binding Globulin. Clin. Endocrinol. (Oxf.) 1974, 3, 69–96. [Google Scholar] [CrossRef]
  19. Harman, S.M. Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men. J. Clin. Endocrinol. Metab. 2001, 86, 724–731. [Google Scholar] [CrossRef]
  20. Handelsman, D.J.; Sikaris, K.; Ly, L.P. Estimating age-specific trends in circulating testosterone and sex hormone-binding globulin in males and females across the lifespan. Ann. Clin. Biochem. 2015, 53, 377–384. [Google Scholar] [CrossRef] [Green Version]
  21. Liu, Y.-J.; Shen, X.-B.; Yu, N.; Shang, X.-J.; Gu, Y.-Q.; Zuo, L.-D.; Xiong, C.-L.; Ye, Z.; Zhou, Y.-Z. Prevalence of late-onset hypogonadism among middle-aged and elderly males in China: Results from a national survey. Asian J. Androl. 2020, 23, 170–177. [Google Scholar]
  22. Veldhuis, J.D.; Dyer, R.B.; Trushin, S.A.; Bondar, O.P.; Singh, R.J.; Klee, G.G. Immunologic and mass-spectrometric estimates of SHBG concentrations in healthy women. Metabolism 2014, 63, 783–792. [Google Scholar] [CrossRef] [Green Version]
  23. Pasquali, R.; Vicennati, V.; Bertazzo, D.; Casimirri, F.; Pascal, G.; Tortelli, O.; Labate, A.M. Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group. Metabolism 1997, 46, 5–9. [Google Scholar] [CrossRef]
  24. Davison, S.L.; Bell, R.; Donath, S.; Montalto, J.G.; Davis, S.R. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab. 2005, 90, 3847–3853. [Google Scholar] [CrossRef] [PubMed]
  25. Burger, H.G.; Dudley, E.C.; Cui, J.; Dennerstein, L.; Hopper, J.L. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J. Clin. Endocrinol. Metab. 2000, 85, 2832–2838. [Google Scholar] [CrossRef] [PubMed]
  26. Rannevik, G.; Jeppsson, S.; Johnell, O.; Bjerre, B.; Laurell-Borulf, Y.; Svanberg, L. A longitudinal study of the perimenopausal transition: Altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995, 61, 67–77. [Google Scholar] [CrossRef] [PubMed]
  27. Elmlinger, M.W.; Kühnel, W.; Wormstall, H.; Döller, P.C. Reference intervals for testosterone, androstenedione and SHBG levels in healthy females and males from birth until old age. Clin. Lab. 2005, 51, 625–632. [Google Scholar]
  28. Maggio, M.; Lauretani, F.; Basaria, S.; Ceda, G.P.; Bandinelli, S.; Metter, E.J.; Bos, A.J.; Ruggiero, C.; Ceresini, G.; Paolisso, G.; et al. Sex hormone binding globulin levels across the adult lifespan in women—The role of body mass index and fasting insulin. J. Endocrinol. Investig. 2008, 31, 597–601. [Google Scholar] [CrossRef] [Green Version]
  29. Subramnya, V.; Zhao, D.; Ouyang, P.; Lima, J.A.; Vaidya, D.; Ndumele, C.E.; Bluemke, D.A.; Shah, S.J.; Guallar, E.; Nwabuo, C.C.; et al. Sex hormone levels and change in left ventricular structure among men and post-menopausal women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas 2018, 108, 37–44. [Google Scholar] [CrossRef]
  30. Moon, H.; Choi, I.; Kim, S.; Ko, H.; Shin, J.; Lee, K.; Sung, J.; Song, Y.M. Cross-sectional association between testosterone, sex hormone-binding globulin and metabolic syndrome: The Healthy Twin Study. Clin. Endocrinol. (Oxf.) 2017, 87, 523–531. [Google Scholar] [CrossRef]
  31. Wallace, I.R.; McKinley, M.C.; Bell, P.M.; Hunter, S.J. Sex hormone binding globulin and insulin resistance. Clin. Endocrinol. (Oxf.) 2013, 78, 321–329. [Google Scholar] [CrossRef] [Green Version]
  32. Perry, J.R.B.; Weedon, M.N.; Langenberg, C.; Jackson, A.U.; Lyssenko, V.; Sparsø, T.; Thorleifsson, G.; Grallert, H.; Ferrucci, L.; Maggio, M.; et al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum. Mol. Genet. 2009, 19, 535–544. [Google Scholar] [CrossRef] [Green Version]
  33. Mingrone, G.; Greco, A.V.; Giancaterini, A.; Scarfone, A.; Castagneto, M.; Pugeat, M. Sex hormone-binding globulin levels and cardiovascular risk factors in morbidly obese subjects before and after weight reduction induced by diet or malabsorptive surgery. Atherosclerosis 2002, 161, 455–462. [Google Scholar] [CrossRef]
  34. Wang, Q.; Würtz, P.; Auro, K.; Morin-Papunen, L.; Kangas, A.J.; Soininen, P.; Tiainen, M.; Tynkkynen, T.; Joensuu, A.; Havulinna, A.S.; et al. Effects of hormonal contraception on systemic metabolism: Cross-sectional and longitudinal evidence. Int. J. Epidemiol. 2016, 45, 1445–1457. [Google Scholar] [CrossRef] [PubMed]
  35. Olszanecka, A.; Kawecka-Jaszcz, K.; Czarnecka, D. Association of free testosterone and sex hormone binding globulin with metabolic syndrome and subclinical atherosclerosis but not blood pressure in hypertensive perimenopausal women. Arch. Med. Sci. 2016, 12, 521–528. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Xiao, H.Y.; Lu, Y.H.; Gong, Y.P.; Cheng, X.L.; Tian, H.; Li, C.L. Correlation of serum sex hormone levels with metabolic syndrome in elderly men. Zhonghua Yi Xue Za Zhi 2016, 96, 702–706. [Google Scholar] [PubMed]
  37. Seyfart, T.; Friedrich, N.; Kische, H.; Bülow, R.; Wallaschofski, H.; Völzke, H.; Nauck, M.; Keevil, B.G.; Haring, R. Association of sex hormones with physical, laboratory, and imaging markers of anthropometry in men and women from the general population. PLoS ONE 2018, 13, e0189042. [Google Scholar] [CrossRef] [Green Version]
  38. Brand, J.S.; Rovers, M.M.; Yeap, B.B.; Schneider, H.J.; Tuomainen, T.P.; Haring, R.; Corona, G.; Onat, A.; Maggio, M.; Bouchard, C.; et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: An individual participant data meta-analysis of observational studies. PLoS ONE 2014, 14, e100409. [Google Scholar] [CrossRef] [Green Version]
  39. Siddiqui, K.; Al-Rubeaan, K.; Nawaz, S.S.; Aburisheh, K.H.; Alaabdin, A.M.Z.; Tolba, I.A. Serum Sex Hormone Binding Globulin (SHBG) Relation with Different Components of Metabolic Syndrome in Men with Type 2 Diabetes. Horm. Metab. Res. 2018, 50, 138–144. [Google Scholar] [CrossRef]
  40. Kim, C.; Dabelea, D.; Kalyani, R.R.; Christophi, C.A.; Bray, G.A.; Pi-Sunyer, X.; Darwin, C.H.; Yalamanchi, S.; Barrett-Connor, E.; Golden, S.H.; et al. Changes in visceral adiposity, subcutaneous adiposity, and sex hormones in the diabetes prevention program. J. Clin. Endocrinol. Metab. 2017, 102, 3381–3389. [Google Scholar] [CrossRef]
  41. Maggio, M.; Lauretani, F.; Ceda, G.P.; Bandinelli, S.; Basaria, S.; Ble, A.; Egan, J.; Paolisso, G.; Najjar, S.; Jeffrey Metter, E.; et al. Association between hormones and metabolic syndrome in older Italian men. J. Am. Geriatr. Soc. 2006, 54, 1832–1838. [Google Scholar] [CrossRef] [Green Version]
  42. Watts, E.L.; Appleby, P.N.; Albanes, D.; Black, A.; Chan, J.M.; Chen, C.; Cirillo, P.M.; Cohn, B.A.; Cook, M.B.; Donovan, J.L.; et al. Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men. PLoS ONE 2017, 12, e0187741. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Zimmerman, Y.; Eijkemans, M.J.C.; Coelingh Bennink, H.J.T.; Blankenstein, M.A.; Fauser, B.C.J.M. The effect of combined oral contraception on testosterone levels in healthy women: A systematic review and meta-analysis. Hum. Reprod. Update 2014, 20, 76–105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Aribas, E.; Kavousi, M.; Laven, J.S.E.; Ikram, M.A.; Roeters Van Lennep, J.E. Aging, Cardiovascular Risk, and SHBG Levels in Men and Women from the General Population. J. Clin. Endocrinol. Metab. 2021, 106, 2890–2900. [Google Scholar] [CrossRef] [PubMed]
  45. Niță, A.-R.; Knock, G.A.; Heads, R.J. Signalling mechanisms in the cardiovascular protective effects of estrogen: With a focus on rapid/membrane signalling. Curr. Res. Physiol. 2021, 4, 103–118. [Google Scholar] [CrossRef] [PubMed]
  46. Basualto-Alarcón, C.; Llanos, P.; García-Rivas, G.; Troncoso, M.F.; Lagos, D.; Barrientos, G.; Estrada, M. Classic and Novel Sex Hormone Binding Globulin Effects on the Cardiovascular System in Men. Int. J. Endocrinol. 2021, 2021, e5527973. [Google Scholar] [CrossRef] [PubMed]
  47. Balogh, A.; Karpati, E.; Schneider, A.E.; Hetey, S.; Szilagyi, A.; Juhasz, K.; Laszlo, G.; Hupuczi, P.; Zavodszky, P.; Papp, Z.; et al. Sex hormone-binding globulin provides a novel entry pathway for estradiol and influences subsequent signaling in lymphocytes via membrane receptor. Sci. Rep. 2019, 9, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Ng, K.M.; Catalano, M.G.; Pinós, T.; Selva, D.M.; Avvakumov, G.V.; Munell, F.; Hammond, G.L. Evidence that fibulin family members contribute to the steroid-dependent extravascular sequestration of sex hormone-binding globulin. J. Biol. Chem. 2006, 281, 15853–15861. [Google Scholar] [CrossRef] [Green Version]
  49. Hammes, A.; Andreassen, T.K.; Spoelgen, R.; Raila, J.; Hubner, N.; Schulz, H.; Metzger, J.; Schweigert, F.J.; Luppa, P.B.; Nykjaer, A.; et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005, 122, 751–762. [Google Scholar] [CrossRef] [Green Version]
  50. Caldwell, J.D.; Shapiro, R.A.; Jirikowski, G.F.; Suleman, F. Internalization of sex hormone-binding globulin into neurons and brain cells in vitro and in vivo. Neuroendocrinology 2007, 86, 84–93. [Google Scholar] [CrossRef]
  51. Fortunati, N.; Catalano, M.G.; Boccuzzi, G.; Frairia, R. Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer. Mol. Cell. Endocrinol. 2010, 316, 86–92. [Google Scholar] [CrossRef] [Green Version]
  52. Hong, H.; Branham, W.S.; Ng, H.W.; Moland, C.L.; Dial, S.L.; Fang, H.; Perkins, R.; Sheehan, D.; Tong, W. Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and α-fetoprotein. Toxicol. Sci. 2015, 143, 333–348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Reports 05 00005 g001 550
Figure 1. The linear plots indicate the geometric means of serum sex hormone-binding globulin (SHBG) levels in men (■) and women (●) in decades of age 20–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, and 70–81 years. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, data collected between 1993 and 1996 in Central Italy and serum SHBG levels analysed in 2016 [13,14,15].
Figure 1. The linear plots indicate the geometric means of serum sex hormone-binding globulin (SHBG) levels in men (■) and women (●) in decades of age 20–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, and 70–81 years. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, data collected between 1993 and 1996 in Central Italy and serum SHBG levels analysed in 2016 [13,14,15].
Reports 05 00005 g001
Table
Table 1. Sex Hormone-Binding Globulin (SHBG) distribution by age groups and sex. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, men and women aged 20–81 years [13,14,15].
Table 1. Sex Hormone-Binding Globulin (SHBG) distribution by age groups and sex. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, men and women aged 20–81 years [13,14,15].
SHBG (nm/L)—MenSHBG (nm/L)—Women
Age Groups (Years)nMeanStd DevIC 95% of MeanMedianMinMaxnMeanStd DevIC 95% of MeanMedianMinMax
20–2911632.412.630.134.729.812.275.521687.655.980.195.169.013.2246.4
30–3922932.813.031.234.630.79.277.436077.151.571.782.460.111.4249.4
40–4926437.818.335.640.035.112.7203.246563.737.260.367.156.37.0246.0
50–5925743.117.341.045.341.410.0112.447550.125.947.852.445.710.6220.5
60–6923250.220.047.652.848.08.5197.348952.924.450.855.148.99.4184.0
70–817857.121.952.162.054.222.9148.723160.425.157.163.654.517.7145.6
20–81117641.218.940.142.337.98.5203.2223662.638.761.064.253.47.0249.4
Data collected between 1993 and 1996 in Central Italy and serum SHBG levels analyzed in 2016. CI: confidence interval. Mean men age (standard deviation): 48.6 nm/L (14.3); mean women age (standard deviation): 50.61 nm/L (14.4).
Table
Table 2. Sex Hormone-Binding Globulin (SHBG) tertiles by age groups and sex. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, men and women aged 20–81 years [13,14,15].
Table 2. Sex Hormone-Binding Globulin (SHBG) tertiles by age groups and sex. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, men and women aged 20–81 years [13,14,15].
Men
SHBG (nm/L)
TotalFirst TertileSecondTertileThirdTertile
AgeClass(Years)n%nMinMaxnMinMaxnMinMax
20–3934529.31159.226.111626.236.511436.677.4
40–5952144.317410.031.117431.245.217345.3203.2
60–8131026.41038.541.310341.556.510456.9197.3
20–811176 392 393 391
Women
SHBG (nm/L)
TotalFirst TertileSecond TertileThird Tertile
Age Class(Years)n%nMinMaxnMinMaxnMinMax
20–3957625.819211.450.619250.783.619284.3249.4
40–5994042.03157.040.331240.461.131361.7246.0
60–8172032.22409.441.724042.061.624061.7184.0
20–812236 747 744 745
Data collected between 1993 and 1996 in Central Italy and serum SHBG levels analyzed in 2016.
Table
Table 3. Baseline characteristics by Sex Hormone-Binding Globulin (SHBG) tertiles and age groups. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, men aged 20–81 years [13,14,15].
Table 3. Baseline characteristics by Sex Hormone-Binding Globulin (SHBG) tertiles and age groups. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, men aged 20–81 years [13,14,15].
Men 20–39
Years Old		SHBG First TertileSHBG Second TertileSHBGThird TertileANOVA
p-Value
Risk FactorsnMeanstd95% CInMeanstd95% CInMeanstd95% CI
SHBG (nm/L)115203.719.420.711630.73.130.131.311447.69.645.849.4<0.0001
Age (years)11531.1530.23211630.75.429.731.711431.84.830.932.70.2084
Systolic BP(mmHg)115132.110.5130134116130.316127133114125.512.61231280.0006
Diastolic BP(mmHg)11582.910.480.984.811680.31477.882.911478.410.876.480.40.0189
BMI (Kg/m2)11526.93.126.327.4116263.325.426.711424.63.623.925.3<0.0001
Glycemia (mg/dL)11585.1118387.111684.71981.388.111481.48.879.8830.0767
Cholesterol (mg/dL)115211.645.3203220116202.543195210114204.157.71932150.3269
HDL(mg/dL)1154310.541.14511645.81143.847.811445.911.443.8480.0767
Triglycerides (mg/dL)115192129168216116155.6165125186114169.82151302100.2745
Testosterone (nm/L)11516.84.715.917.711421.55.120.522.490265.224.927.1<0.0001
Risk Conditionsn% 95% CIn% 95% CIn% 95% CIChi-Squared p-Value
Smoking5144.3 35.153.65244.8 35.6547162.3 53.271.30.0084
Hypertension4740.9 31.7503227.6 19.335.82118.4 11.225.60.0008
Hypercholesterolemia2925.2 17.233.32118.1 1125.21513.2 6.919.50.0637
Diabetes10.9 02.621.7 04.100 --0.3711
Men 40–59
Years Old		SHBG First TertileSHBG Second TertileSHBG Third TertileANOVA p-Value
Risk FactorsnMeanstd95% CInMeanstd95% CInMeanstd95% CI
SHBG (nm/L)174244.723.324.717437.9437.338.517359.517.15762.1<0.0001
Age (years)174485.647.248.917449.55.548.750.417351.25.350.452<0.0001
Systolic BP(mmHg)174138.119135141174136.519134139173136.818.91341400.7089
Diastolic BP(mmHg)17488.91287.290.717487.21285.588.917386.412.284.688.30.136
BMI (Kg/m2)17328.13.127.628.517427.63.127.12817227.13.826.527.70.0291
Glycemia (mg/dL)174942091.19717291.61888.994.317393.124.889.496.90.5631
Cholesterol (mg/dL)174216.539211222172222.74421622917322645.92192330.1125
HDL(mg/dL)17443.81142.245.417245.11243.346.817346.711.744.948.40.0604
Triglycerides (mg/dL)174194.3131175214172176.8131157197173165.61151481830.102
Testosterone (nm/L)17315.33.914.715.917420.14.319.520.814025.2524.326<0.0001
Risk Conditionsn% 95% CIn% 95% CIn% 95% CIChi-Squared p-Value
Smoking5028.7 21.935.57140.8 33.448.28146.83.839.354.30.002
Hypertension9856.3 48.963.89152.3 44.859.883483.840.555.50.2979
Hypercholesterolemia5229.9 2336.85833.3 26.340.46738.73.731.446.10.2152
Diabetes95.2 1.88.584.7 1.57.895.21.71.98.50.9658
Men 60–81
Years Old		SHBG First TertileSHBG Second TertileSHBG Third TertileANOVA p-Value
Risk FactorsnMeanstd95% CInMeanstd95% CInMeanstd95% CI
SHBG (nm/L)10333.16.231.934.310348.84.24849.710473.619.769.877.5<0.0001
Age (years)10365.54.764.666.4103664.465.166.910467.54.666.668.40.0042
Systolic BP(mmHg)103156.225.3151161103152.924148158104154.925.41501600.6327
Diastolic BP(mmHg)10388.413.885.791.110384.51381.987.110486.314.783.589.20.1366
BMI (Kg/m2)10228.83.92829.610227.63.326.928.210327.53.626.828.20.0139
Glycemia (mg/dL)10310230.596108103100.12395.610510492.515.889.495.60.0114
Cholesterol (mg/dL)103234.741.5227243103225.947217235104225.839.32182330.2272
HDL(mg/dL)10348.115.445.151.110347.51444.850.210449.814.64752.70.4805
Triglycerides (mg/dL)103205126180230103169.195151188104163.81181411870.0189
Testosterone (nm/L)10316.63.915.817.49921.35.120.222.387265.824.827.2<0.0001
Risk conditionsn% 95% CIn% 95% CIn% 95% CIChi-Squared p-Value
Smoking2524.3 15.932.735344.724.743.34240.44.830.8500.0458
Hypertension8279.6 71.787.57976.74.268.4857370.24.561.379.10.272
Hypercholesterolemia4745.6 35.855.44543.74.933.953.43735.64.726.244.90.2972
Diabetes1211.7 5.3181615.53.68.422.654.82.10.690.0403
Data collected between 1993 and 1996 in Central Italy. std: standard deviation; CI: confidence interval; BMI, body mass index; BP, blood pressure. ANOVA model and chi-squared test compare respectively mean values and prevalence among tertiles. Hypertension: mean of two consecutive blood pressure values of systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or under pharmacological treatment. Hypercholesterolemia: total cholesterol ≥ 240 mg/dL (6.2 mmol/L) or under regular lipid lowering treatment. Diabetics: persons with blood glucose ≥ 126 mg/dL (7 mmol/L) or under antidiabetic treatment (oral hypoglycemic medication and/or insulin) or with self-reported diabetes at the time of the screening).
Table
Table 4. Baseline characteristics by Sex Hormone-Binding Globulin (SHBG) tertiles and age groups. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, women aged 20–81 years [13,14,15].
Table 4. Baseline characteristics by Sex Hormone-Binding Globulin (SHBG) tertiles and age groups. The Malattie Aterosclerotiche Istituto Superiore di Sanità (MATISS) study, women aged 20–81 years [13,14,15].
Women 20–39 Years OldSHBG First TertileSHBG Second TertileSHBG Third TertileANOVA p-Value
Risk FactorsnMeanstd95% CInMeanstd95% CInMeanstd95% CI
SHBG (nm/L)19236.19.734.737.519264.69.463.365.9192142.448136149<0.0001
Age (years)19232.35.231.633.119231.35.230.53219231.35.230.632.10.0858
Systolic BP(mmHg)192123.214121125192119.612118121192121.7141201240.0322
Diastolic BP(mmHg)19278.31176.779.919273.29.871.874.619276.11174.577.6<0.0001
BMI (Kg/m2)19226.74.62627.319223.83.623.324.319224.13.623.624.6<0.0001
Glycemia (mg/dL)19279.21477.281.319275.68.574.376.819274.88.973.676.10.0001
Cholesterol (mg/dL)192192.736188198192184.231180189192204.642199211<0.0001
HDL(mg/dL)19250.31048.851.819255.29.853.856.619258.81356.960.6<0.0001
Triglycerides (mg/dL)192102.65694.611119278.63373.983.3192114.877104126<0.0001
Testosterone (nm/L)1881.20.41.11.21901.10.41.11.21831.10.411.10.0588
Risk Conditionsn% 95% CIn% 95% CIn% 95% CIChi-Squared p-Value
Smoking6332.8 26.139.56031.3 24.637.95830.2 23.736.80.8581
Hypertension4221.9 1627.8189.4 5.213.52915.1 1020.20.0032
Hypercholesterolemia2110.9 6.515.463.1 0.65.64020.8 1526.6<0.0001
Diabetes31.6 03.300 --00 --0.049
Menstrual cycles18497.9 95.810018698.4 96.610017897.8 95.71000.55
Estrogen therapy *00 --00 --00 ---
Contracceptive drugs **105.6 2.292916.1 10.721.510358.9 51.566.2<0.0001
Women 40–59 Years OldSHBG First TertileSHBG Second TertileSHBG Third TertileANOVA p-Value
Risk FactorsnMeanstd95% CInMeanstd95% CInMeanstd95% CI
SHBG (nm/L)31529.67.428.730.431250.5649.851.231390.63486.894.5<0.0001
Age (years)315515.150.451.631249.95.849.350.631348.25.647.648.8<0.0001
Systolic BP(mmHg)31414622144148312139.921138142313133.619132136<0.0001
Diastolic BP(mmHg)31489.81388.491.231286.51385.18831382.71381.384.1<0.0001
BMI (Kg/m2)31431.44.930.831.931229.44.528.929.931326.74.126.327.2<0.0001
Glycemia (mg/dL)31592.23288.695.731284.12081.986.431183.21881.285.1<0.0001
Cholesterol (mg/dL)315227.140223232312224.540220229311220.2412162250.1041
HDL(mg/dL)31550.61249.35231253.91352.455.431157.3125658.6<0.0001
Triglycerides (mg/dL)315148.385139158312126.169118134311108.755103115<0.0001
Testosterone (nm/L)2891.11.80.91.33051.11.20.91.229710.611.10.9529
Risk Conditionsn% 95% CIn% 95% CIn% 95% CIChi-Squared p-Value
Smoking196 3.48.74113.1 9.416.95316.9 12.821.10.0001
Hypertension22371 6676.118057.7 52.263.213242.2 36.747.7<0.0001
Hypercholesterolemia10834.3 2939.610533.7 28.438.99229.4 24.334.50.3633
Diabetes216.7 3.99.492.9 14.861.9 0.43.50.0048
Menstrual cycles7724.6 19.829.410634 28.739.316151.4 45.957<0.0001
Estrogen therapy *135.6 2.68.6125.9 2.69.1106.6 2.610.60.9161
Contracceptive drugs **32.8 05.932.4 05.12413.1 8.218.10.0002
Women 60–81 Years OldSHBG First TertileSHBG Second TertileSHBG Third TertileANOVA p-Value
Risk FactorsnMeanstd95% CInMeanstd95% CInMeanstd95% CI
SHBG (nm/L)24031.76.930.832.524051.1550.551.724083.32080.785.9<0.0001
Age (years)24066.14.765.566.724067.24.966.667.924067.64.86768.20.002
Systolic BP(mmHg)24016125158164240159.725157163239155.1231521580.0192
Diastolic BP(mmHg)24091.71489.993.424088.81387.290.323986.91285.388.40.0002
BMI (Kg/m2)23932.34.831.732.924030.64.43031.123828.34.727.728.9<0.0001
Glycemia (mg/dL)240101.63796.910624091.82588.694.924087.51685.489.6<0.0001
Cholesterol (mg/dL)240237.640233243240234.240229239240234.1392292390.5391
HDL(mg/dL)24049.61248.151.224053.11251.554.624055.31353.756.9<0.0001
Triglycerides (mg/dL)240178.292167190240149.971141159240132.653126139<0.0001
Testosterone (nm/L)2271.220.91.42311.10.611.22301.1111.30.7892
Risk Conditionsn% 95% CIn% 95% CIn% 95% CIChi-Squared p-Value
Smoking93.8 1.36.272.9 0.85.152.1 0.33.90.5546
Hypertension21690 86.293.820685.8 81.490.320184.1 79.488.80.1489
Hypercholesterolemia11447.5 41.153.910644.2 37.850.511246.7 40.3530.7478
Diabetes4016.7 11.921.4166.7 3.59.8177.1 3.810.40.0002
Menstrual cycles00 --00 --10.4 01.20.3658
Estrogen therapy *93.8 1.46.393.8 1.46.3104.3 1.770.944
Contracceptive drugs **00 --00 --00 ---
Data collected between 1993 and 1996 in Central Italy. std: standard deviation; CI: confidence interval; BMI, body mass index; BP, blood pressure. ANOVA model and chi-squared test compare respectively mean values and prevalence among tertiles. Hypertension: mean of two consecutive blood pressure values of systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or under pharmacological treatment. Hypercholesterolemia: total cholesterol ≥ 240 mg/dL (6.2 mmol/L) or under regular lipid lowering treatment. Diabetics: persons with blood glucose ≥ 126 mg/dL (7 mmol/L) or under antidiabetic treatment (oral hypoglycemic medication and/or insulin) or with self-reported diabetes at the time of the screening). * Only for those without regular cycles or with not regular cycles. ** Only for those with regular cycles.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Buttari, B.; Riganò, R.; Palmieri, L.; Lo Noce, C.; Blankenberg, S.; Zeller, T.; Vannucchi, S.; Di Lonardo, A.; Gabbianelli, M.; Donfrancesco, C. Sex Hormone-Binding Globulin and Its Association to Cardiovascular Risk Factors in an Italian Adult Population Cohort. Reports 2022, 5, 5. https://doi.org/10.3390/reports5010005

AMA Style

Buttari B, Riganò R, Palmieri L, Lo Noce C, Blankenberg S, Zeller T, Vannucchi S, Di Lonardo A, Gabbianelli M, Donfrancesco C. Sex Hormone-Binding Globulin and Its Association to Cardiovascular Risk Factors in an Italian Adult Population Cohort. Reports. 2022; 5(1):5. https://doi.org/10.3390/reports5010005

Chicago/Turabian Style

Buttari, Brigitta, Rachele Riganò, Luigi Palmieri, Cinzia Lo Noce, Stefan Blankenberg, Tanja Zeller, Serena Vannucchi, Anna Di Lonardo, Marco Gabbianelli, and Chiara Donfrancesco. 2022. "Sex Hormone-Binding Globulin and Its Association to Cardiovascular Risk Factors in an Italian Adult Population Cohort" Reports 5, no. 1: 5. https://doi.org/10.3390/reports5010005

APA Style

Buttari, B., Riganò, R., Palmieri, L., Lo Noce, C., Blankenberg, S., Zeller, T., Vannucchi, S., Di Lonardo, A., Gabbianelli, M., & Donfrancesco, C. (2022). Sex Hormone-Binding Globulin and Its Association to Cardiovascular Risk Factors in an Italian Adult Population Cohort. Reports, 5(1), 5. https://doi.org/10.3390/reports5010005

Article Metrics

Back to TopTop